AstraZeneca ovarian cancer drug approved for wider use

03:35 EDT 18 Aug 2017 | Proactive Investors

American regulators have given the green light for the wider usage of an ovarian cancer drug. Sold by AstraZeneca PLC (LON:AZN) and Merck & Co Inc (NYSE:MRK), Lynparza will now be prescribed to patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The US Food & Drug Administration also agreed a switch to two-tablets a day from the current eight capsules regimen. Lynparza was initially approved to be given to women with advanced ovarian cancer who had stopped responding to three rounds of chemotherapy. PARP inhibitor  It is one of a class of drugs called PARP inhibitors which prevent cancer cells from repairing damaged DNA, causing them to die. "Physicians have almost three years of clinical experience with Lynparza on the market and we are now pleased to bring this important medicine, in a new tablet formulation, to a broader group of women,” said AZ’s Sean Bohen. “[The] approvals validate more than 10 years of dedicated research behind Lynparza, the world's first PARP inhibitor, which now provides oncologists with the greater flexibility for use in terms of treatment settings. “It builds on our recently-announced collaboration with Merck, which aims to further increase the number of treatment options available to patients." Researchers are assessing the potential of using Lynparza to treat pancreatic and prostate cancer.

Original Article: AstraZeneca ovarian cancer drug approved for wider use


More From BioPortfolio on "AstraZeneca ovarian cancer drug approved for wider use"

Quick Search


Relevant Topics

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...